Research graph
References from Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US
10.1001/jamanetworkopen.2023.1439 · 2023 · External reference
Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
10.1056/nejmoa2214122 · 2023 · External reference
National trends in active surveillance for prostate cancer: validation of Medicare claims-based algorithms
10.1016/j.urology.2018.06.037 · 2018 · External reference
Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis
10.1016/j.eururo.2014.11.039 · 2015 · External reference
Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer
10.1016/j.eururo.2011.08.041 · 2011 · External reference
Adverse effects of androgen deprivation therapy and strategies to mitigate them
10.1016/j.eururo.2014.07.010 · 2015 · External reference
Risk of cognitive effects in comorbid patients with prostate cancer treated with androgen receptor inhibitors
10.1016/j.clgc.2021.03.014 · 2021 · External reference
Development of a comorbidity index using physician claims data
10.1016/s0895-4356(00)00256-0 · 2000 · External reference
Modifiable cardiovascular risk factors amongst men with and without prostate cancer in a large, prospective registry
10.1016/j.clgc.2025.102340 · 2025 · External reference
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
10.1200/jco.2006.06.2497 · 2006 · External reference
Risk of fracture after androgen deprivation for prostate cancer
10.1056/nejmoa041943 · 2005 · External reference
Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies
10.1371/journal.pone.0107516 · 2014 · External reference
Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer
10.1056/nejmoa2403365 · 2024 · External reference
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
10.1016/s0140-6736(19)31131-6 · 2019 · External reference
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics
10.1111/bju.16482 · 2024 · External reference
Advanced age portends poorer prognosis after radical prostatectomy: a single center experience
10.1007/s40520-022-02213-w · 2022 · External reference
Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991
10.1200/jco.2015.64.8055 · 2016 · External reference
Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial
10.1200/jco.22.02390 · 2023 · External reference
Clinical-genomic characterization unveils more aggressive disease features in elderly prostate cancer patients with low-grade disease
10.1016/j.euf.2020.02.008 · 2021 · External reference
Trends in active surveillance for men with intermediate-risk prostate cancer
10.1001/jamanetworkopen.2024.29760 · 2024 · External reference
Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study
10.1371/journal.pone.0279981 · 2023 · External reference
Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications
10.1016/j.juro.2007.05.135 · 2007 · External reference
Testosterone recovery after androgen deprivation therapy in localised prostate cancer: long-term data from two randomised trials
10.1016/j.radonc.2024.110256 · 2024 · External reference
Impact of sequencing of androgen suppression and radiation therapy on testosterone recovery in localized prostate cancer
10.1016/j.ijrobp.2020.06.017 · 2020 · External reference
Impact of androgen deprivation therapy on cognitive function of elderly men with prostate cancer
2024 · External reference
What are the priorities for research of older people living in their own home, including those living with frailty? A systematic review and content analysis of studies reporting older people’s priorities and unmet needs
10.1093/ageing/afad232 · 2024 · External reference
What matters to people aged 80 and over regarding ambulatory care? A systematic review and meta-synthesis of qualitative studies
10.1007/s10433-021-00633-7 · 2022 · External reference
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial
10.1111/bju.15887 · 2023 · External reference
Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
10.18433/jpps31003 · 2020 · External reference
A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
10.3389/fonc.2021.627083 · 2021 · External reference
Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US
10.1001/jamanetworkopen.2023.1439 · ExternalCitation · doi-reference
Trends in active surveillance for men with intermediate-risk prostate cancer
10.1001/jamanetworkopen.2024.29760 · ExternalCitation · doi-reference
What matters to people aged 80 and over regarding ambulatory care? A systematic review and meta-synthesis of qualitative studies
10.1007/s10433-021-00633-7 · ExternalCitation · doi-reference
Advanced age portends poorer prognosis after radical prostatectomy: a single center experience
10.1007/s40520-022-02213-w · ExternalCitation · doi-reference
Risk of cognitive effects in comorbid patients with prostate cancer treated with androgen receptor inhibitors
10.1016/j.clgc.2021.03.014 · ExternalCitation · doi-reference
Modifiable cardiovascular risk factors amongst men with and without prostate cancer in a large, prospective registry
10.1016/j.clgc.2025.102340 · ExternalCitation · doi-reference
Clinical-genomic characterization unveils more aggressive disease features in elderly prostate cancer patients with low-grade disease
10.1016/j.euf.2020.02.008 · ExternalCitation · doi-reference
Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer
10.1016/j.eururo.2011.08.041 · ExternalCitation · doi-reference
Adverse effects of androgen deprivation therapy and strategies to mitigate them
10.1016/j.eururo.2014.07.010 · ExternalCitation · doi-reference
Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis
10.1016/j.eururo.2014.11.039 · ExternalCitation · doi-reference
Impact of sequencing of androgen suppression and radiation therapy on testosterone recovery in localized prostate cancer
10.1016/j.ijrobp.2020.06.017 · ExternalCitation · doi-reference
Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications
10.1016/j.juro.2007.05.135 · ExternalCitation · doi-reference
Testosterone recovery after androgen deprivation therapy in localised prostate cancer: long-term data from two randomised trials
10.1016/j.radonc.2024.110256 · ExternalCitation · doi-reference
National trends in active surveillance for prostate cancer: validation of Medicare claims-based algorithms
10.1016/j.urology.2018.06.037 · ExternalCitation · doi-reference
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
10.1016/s0140-6736(19)31131-6 · ExternalCitation · doi-reference
Development of a comorbidity index using physician claims data
10.1016/s0895-4356(00)00256-0 · ExternalCitation · doi-reference
Risk of fracture after androgen deprivation for prostate cancer
10.1056/nejmoa041943 · ExternalCitation · doi-reference
Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
10.1056/nejmoa2214122 · ExternalCitation · doi-reference
Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer
10.1056/nejmoa2403365 · ExternalCitation · doi-reference
What are the priorities for research of older people living in their own home, including those living with frailty? A systematic review and content analysis of studies reporting older people’s priorities and unmet needs
10.1093/ageing/afad232 · ExternalCitation · doi-reference
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial
10.1111/bju.15887 · ExternalCitation · doi-reference
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics
10.1111/bju.16482 · ExternalCitation · doi-reference
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
10.1200/jco.2006.06.2497 · ExternalCitation · doi-reference
Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991
10.1200/jco.2015.64.8055 · ExternalCitation · doi-reference
Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial
10.1200/jco.22.02390 · ExternalCitation · doi-reference
Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies
10.1371/journal.pone.0107516 · ExternalCitation · doi-reference
Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study
10.1371/journal.pone.0279981 · ExternalCitation · doi-reference
Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
10.18433/jpps31003 · ExternalCitation · doi-reference
A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
10.3389/fonc.2021.627083 · ExternalCitation · doi-reference
